Sarepta Therapeutics (NASDAQ:SRPT) Given Hold Rating at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "hold" rating restated by Needham & Company LLC in a report issued on Thursday, MarketBeat.com reports. They presently have a $50.00 price objective on the biotechnology company's stock. Needham & Company LLC's target price would suggest a potential upside of 263.93% from the stock's previous close.

SRPT has been the subject of a number of other research reports. Robert W. Baird lifted their target price on Sarepta Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Thursday. JPMorgan Chase & Co. reduced their target price on Sarepta Therapeutics from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Thursday, July 10th. William Blair reaffirmed a "market perform" rating on shares of Sarepta Therapeutics in a report on Friday, June 20th. Oppenheimer dropped their price target on Sarepta Therapeutics from $123.00 to $45.00 and set an "outperform" rating for the company in a research report on Friday, June 20th. Finally, TD Cowen downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price target for the company. in a research report on Wednesday, June 18th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $56.50.

Sarepta Therapeutics Stock Performance

SRPT traded down $8.23 during trading hours on Thursday, hitting $13.74. The stock had a trading volume of 61,886,305 shares, compared to its average volume of 2,632,876. The company's fifty day simple moving average is $28.86 and its 200 day simple moving average is $69.08. Sarepta Therapeutics has a 1 year low of $12.88 and a 1 year high of $150.48. The stock has a market cap of $1.35 billion, a PE ratio of -5.18 and a beta of 0.45. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm's quarterly revenue was up 80.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.73 EPS. Equities analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently bought and sold shares of the stock. Byrne Asset Management LLC purchased a new position in Sarepta Therapeutics in the 1st quarter worth approximately $30,000. Center for Financial Planning Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $31,000. Ancora Advisors LLC increased its stake in shares of Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after buying an additional 300 shares during the period. Banque Transatlantique SA purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $44,000. Finally, Pandora Wealth Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $45,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.